Building upon previous studies, a new study has unearthed critical facts about the basic biology behind the TORC1 pathway, identifying how caloric restriction leads to a chain of effects that activate the protein Maf1, repress RNA transcription, and slow genomic instability, which is one of the primary hallmarks of aging. A long chain of causes…

If humans ever reach an average lifespan of well over 100 years, what is going to happen? Are we going to be bored with such long lives? “Well,” says Prof. Brian Kennedy of the National University of Singapore, “If you ask me: ‘Do I want to have cancer at 75? Do I want have Alzheimer’s…

ResTORbio announced on Friday 15th that its current phase 3 drug trial for respiratory tract infections did not achieve its primary goal. The drug showed promise in earlier phases of testing, but sadly failed to reduce the incidence of respiratory tract infections in patients aged 65 and above. A setback for RTB101 This news has…

The Journal club returns for a Halloween special and this time around, Dr. Oliver Medvedik is taking an in depth look at a recent paper which showed a combination of three drugs had a synergistic effect and increased lifespan greatly in fruit flies. The drugs all target parts of the nutrient sensing system which controls…

Researchers have discovered a new drug that targets the mTOR pathway, which is involved in aging and metabolism. It could function as a caloric restriction mimetic, bringing about similar health benefits. The mTOR pathway The mechanistic target of rapamycin (mTOR) pathway is a part of metabolism and is one of the four major pathways that…

Rapamycin is a promising anti-aging therapeutic derived from a bacterium that was first found on Easter Island (it’s named for Rapa Nui, the official name of Easter Island). It inhibits mTOR (mechanistic target of rapamycin), thus inhibiting the immune system response that would, in some cases, lead to organ rejection. This is the on-label, FDA-approved…

Last year, resTORbio announced the positive results of its phase 2b human trial, which targeted the aging immune system with an immune system-boosting drug. Now, the company has announced the news that its therapy is moving to a phase 3 study later this year after successful negotiation with the FDA. Targeting the mTOR pathway of…

Researchers have discovered a link between the cellular recycling system known as autophagy and the behavior of microglial immune cells during aging. We have discussed the polarization of macrophages in a number of previous articles, and it has become quite a hot topic among researchers in the last few years. Microglia are tissue-resident macrophages in…

A new study takes a look at the relationship between metabolism, aging, and type 2 diabetes and in particular the mTORC1 protein complex, part of the mTOR pathway. The mTOR pathway The mechanistic target of rapamycin (mTOR) pathway is a major part of metabolism and is one of four major pathways that control it; collectively,…

Today, we are pleased to announce that the results are in from a human trial that targets the aging immune system and that an immune system-boosting drug appears to be effective. Targeting TORC1 to boost the immune system As we age, the immune system becomes increasingly poor and unable to detect and fight infections. This…

© 2020 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

       Powered by MMD